VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2020-09-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of IV administration of
VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small
cell lung cancer. The dose escalation portion of the study will determine the maximum
tolerated dose (MTD) of VX15/2503 administered in combination with avelumab.